Article ; Online: N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases.
Arteriosclerosis, thrombosis, and vascular biology
2021 Volume 41, Issue 12, Page(s) 2855–2865
Abstract: While the promise of oligonucleotide therapeutics, such as (chemically modified) ASO (antisense oligonucleotides) and short interfering RNAs, is undisputed from their introduction onwards, their unfavorable pharmacokinetics and intrinsic capacity to ... ...
| Abstract | While the promise of oligonucleotide therapeutics, such as (chemically modified) ASO (antisense oligonucleotides) and short interfering RNAs, is undisputed from their introduction onwards, their unfavorable pharmacokinetics and intrinsic capacity to mobilize innate immune responses, were limiting widespread clinical use. However, these major setbacks have been tackled by breakthroughs in chemistry, stability and delivery. When aiming an intervention hepatic targets, such as lipid and sugar metabolism, coagulation, not to mention cancer and virus infection, introduction of N-acetylgalactosamine aided targeting technology has advanced the field profoundly and by now a dozen of N-acetylgalactosamine therapeutics for these indications have been approved for clinical use or have progressed to clinical trial stage 2 to 3 testing. This technology, in combination with major advances in oligonucleotide stability allows safe and durable intervention in targets that were previously deemed undruggable, such as Lp(a) and PCSK9 (proprotein convertase subtilisin/kexin type 9), at high efficacy and specificity, often with as little as 2 doses per year. Their successful use even the most visionary would not have predicted 2 decades ago. Here, we will review the evolution of N-acetylgalactosamine technology. We shall outline their fundamental design principles and merits, and their application for the delivery of oligonucleotide therapeutics to the liver. Finally, we will discuss the perspectives of N-acetylgalactosamine technology and propose directions for future research in receptor targeted delivery of these gene medicines. |
|---|---|
| MeSH term(s) | Acetylgalactosamine/chemistry ; Cardiovascular Diseases/drug therapy ; Drug Delivery Systems ; Genetic Therapy/methods ; Hepatocytes/drug effects ; Hepatocytes/metabolism ; Humans ; Liver/drug effects ; Liver/metabolism ; Oligonucleotides/administration & dosage ; RNAi Therapeutics |
| Chemical Substances | Oligonucleotides ; Acetylgalactosamine (KM15WK8O5T) |
| Language | English |
| Publishing date | 2021-10-14 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 1221433-4 |
| ISSN | 1524-4636 ; 1079-5642 |
| ISSN (online) | 1524-4636 |
| ISSN | 1079-5642 |
| DOI | 10.1161/ATVBAHA.121.316290 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1705: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.